Depressive and anxiety symptoms during CGRP-targeted migraine prevention: A systematic review and meta-analysis.

Migraine often occurs alongside depression and anxiety, worsening patients' overall health. This study looked at how CGRP-targeted therapies affect these mental health symptoms. CGRP-targeted treatments are effective in reducing migraine frequency. Researchers reviewed multiple studies to see if these therapies also help with depression and anxiety. They searched various databases for relevant studies published until July 2026. The studies included randomized controlled trials and observational studies. They focused on changes in depressive and anxiety symptoms among adults with migraines. The findings were mixed due to differences in study designs and methods used. Some evidence suggests that CGRP therapies may improve mental health symptoms alongside reducing migraine attacks. However, more consistent research is needed to confirm these effects. Understanding the relationship between migraines and mental health can inform better treatment options for patients suffering from both conditions. Clinical relevance: This research indicates that CGRP-targeted therapies might improve both migraine and mental health symptoms, potentially enhancing treatment outcomes for patients with comorbid conditions.